<DOC>
	<DOCNO>NCT01459796</DOCNO>
	<brief_summary>The purpose study determine safety tolerability rilonacept patient gout initiate allopurinol .</brief_summary>
	<brief_title>Study Safety Efficacy Long-Term Rilonacept Treatment Prevention Gout Flares</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Key Inclusion criterion : Male female patient age 18 80 year Previously meet preliminary criterion ARA classification acute arthritis primary gout Serum uric acid great equal 7.5 mg/dL Screening Visit A selfreported history least 2 gout flare year prior screen Key Exclusion criterion : Pregnant nursing , plan become pregnant father child within 3 month receive last dose study drug Patients require dialysis Patients organ transplant Persistent chronic active infection Previous exposure rilonacept Use allopurinol , benzbromarone , febuxostat , probenecid sulfinpyrazone within 84 day prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>